Laurus Labs Limited

rs,

October 20, 2023 To To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street Mumbai – 400001 The Listing Department National Stock Exchange of Indi

₹ 2,406

project pipeline scaled up along with expansion of our strategic manufacturing partnerships   ₹ 2,406 Cr Revenues for H1, declined 23%. Excluding PO, growth was 14% ₹ 356 Cr EBITDA resulted in a margin

23%

h expansion of our strategic manufacturing partnerships   ₹ 2,406 Cr Revenues for H1, declined 23%. Excluding PO, growth was 14% ₹ 356 Cr EBITDA resulted in a margin of 15% with higher upfront expe

14%

anufacturing partnerships   ₹ 2,406 Cr Revenues for H1, declined 23%. Excluding PO, growth was 14% ₹ 356 Cr EBITDA resulted in a margin of 15% with higher upfront expense on resource allocation to

₹ 356

cturing partnerships   ₹ 2,406 Cr Revenues for H1, declined 23%. Excluding PO, growth was 14% ₹ 356 Cr EBITDA resulted in a margin of 15% with higher upfront expense on resource allocation towards gr

15%

evenues for H1, declined 23%. Excluding PO, growth was 14% ₹ 356 Cr EBITDA resulted in a margin of 15% with higher upfront expense on resource allocation towards growth projects and new initiatives.

50%

Chemistry, Bio catalysis, Precision fermentation Stabilization of ARV business and achieved over 50%^ of targeted cost improvement initiatives  Grown Scientific and Commercial advantage to onboar

34%

to treat r/r Lymphoma/Leukemia indication Increased stake in Cell therapy company ImmunoACT to ~34%  CAR-T treatment capacity expansion to  Global supply chain migration leading to service mor

4 billion

n liters under Phased manner) FDF, VTZ Expansion of small molecules DP capabilities at U2 – by 4 billion unit annually New Capacities brought on line in FY23 Expected to come on line in FY24 Future Ca

Rs10

US$ 100mn+ CDMO investment on track  Commercial activity initiated at AH unit  Expect to spend Rs10bn in FY24 Capex  H1 Capex reported at ₹ 385 Cr; 16% of Revenues Continuous investment in dive

₹ 385

cial activity initiated at AH unit  Expect to spend Rs10bn in FY24 Capex  H1 Capex reported at ₹ 385 Cr; 16% of Revenues Continuous investment in diversified portfolio to support growth momentum ^

16%

ity initiated at AH unit  Expect to spend Rs10bn in FY24 Capex  H1 Capex reported at ₹ 385 Cr; 16% of Revenues Continuous investment in diversified portfolio to support growth momentum ^ Vizag